Novavax have recently published positive data from the UK phase 3 study of its COVID-19 vaccine candidate, showing it to be 89.3% effective in preventing coronavirus in participants. Trial data suggests side-effect such as headaches, fatigue and muscle pain may occur less frequently.
For more information click on the link – https://www.theguardian.com/society/2021/nov/24/novavax-expected-to-be-approved-as-fourth-covid-vaccine-in-uk
